{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:01:07Z","timestamp":1791644467114,"version":"4.3.4"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2020,10,17]],"date-time":"2020-10-17T00:00:00Z","timestamp":1602892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Itraconazole is the preferred azole for histoplasmosis in the current Infectious Diseases Society of America guidelines. Voriconazole is increasingly used as treatment for histoplasmosis; it has in vitro activity against Histoplasma capsulatum and has shown success in case reports and small case series, but may have a lower barrier to resistance. No comparative studies have been published.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We constructed a single-center, retrospective cohort of adult patients diagnosed with histoplasmosis from 2002 to 2017. Individual charts were reviewed to gather clinical information, including demographics, clinical features, immune status, treatments, and mortality. Patients were categorized based on the choice of azole and use as an initial treatment or as a step-down therapy from amphotericin B. Initial therapies with other azoles were excluded. Mortality was compared using a multivariable Cox proportional hazards with Heaviside function at 42 days.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We identified 261 cases of histoplasmosis from 2002 to 2017. After excluding patients not treated with itraconazole or voriconazole, 194 patients remained. Of these, 175 (90%) patients received itraconazole and 19 (10%) received voriconazole. There were no significant demographic differences between patient populations receiving either azole as their initial azole treatment. Death at 180 days occurred in 41 patients (23.4%) in the itraconazole group and 6 patients (31.6%) in the voriconazole group. Patients on voriconazole had a statistically significant increase in mortality during the first 42 days after initiation of treatment when compared to patients receiving itraconazole (hazard ratio, 4.30; 95% confidence interval, 1.3\u201313.9; P = .015), when controlled for other risk factors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Voriconazole in histoplasmosis was associated with increased mortality in the first 42 days when compared to itraconazole.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciaa1555","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T11:10:40Z","timestamp":1602846640000},"page":"e3727-e3732","source":"Crossref","is-referenced-by-count":39,"title":["Voriconazole Versus Itraconazole for the Initial and Step-down Treatment of Histoplasmosis: A Retrospective Cohort"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0740-5313","authenticated-orcid":false,"given":"Michael Joshua","family":"Hendrix","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Larson","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana M","family":"Rauseo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasinuch","family":"Rutjanawech","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander D","family":"Franklin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Washington University School of Medicine, St Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G","family":"Powderly","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Spec","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,17]]},"reference":[{"key":"2021121022354567100_CIT0001","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1086\/521259","article-title":"Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America","volume":"45","author":"Wheat","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2021121022354567100_CIT0002","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.idc.2015.10.009","article-title":"Histoplasmosis","volume":"30","author":"Wheat","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"2021121022354567100_CIT0003","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0002-9343(99)80311-8","article-title":"Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome","volume":"98","author":"Wheat","year":"1995","journal-title":"Am J Med"},{"key":"2021121022354567100_CIT0004","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1365-2141.2011.08838.x","article-title":"Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation","volume":"155","author":"Marks","year":"2011","journal-title":"Br J Haematol"},{"key":"2021121022354567100_CIT0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1470-9465.2004.00838.x","article-title":"Voriconazole\u2013a new therapeutic agent with an extended spectrum of antifungal activity","volume":"10(Suppl 1)","author":"Donnelly","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"2021121022354567100_CIT0006","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1128\/AAC.44.6.1734-1736.2000","article-title":"In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum","volume":"44","author":"Li","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121022354567100_CIT0007","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00024720-200304000-00016","article-title":"Intramedullary histoplasmosis spinal cord abscess in a nonendemic region: case report and review of the literature","volume":"16","author":"Hott","year":"2003","journal-title":"J Spinal Disord Tech"},{"key":"2021121022354567100_CIT0008","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.transproceed.2005.01.054","article-title":"Fungal infections in transplant recipients receiving alemtuzumab","volume":"37","author":"Nath","year":"2005","journal-title":"Transplant Proc"},{"key":"2021121022354567100_CIT0009","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1378\/chest.126.3.982","article-title":"A patient with new-onset seizure and mediastinal adenopathy","volume":"126","author":"Truong","year":"2004","journal-title":"Chest"},{"key":"2021121022354567100_CIT0010","doi-asserted-by":"crossref","first-page":"e919724","DOI":"10.12659\/AJCR.919724","article-title":"A case of pulmonary histoplasmosis presenting with hypercalcemia and altered mental status in a patient following allogeneic hematopoietic stem cell transplantation","volume":"21","author":"Rodriguez","year":"2020","journal-title":"Am J Case Rep"},{"key":"2021121022354567100_CIT0011","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1128\/AAC.01148-07","article-title":"Voriconazole use for endemic fungal infections","volume":"53","author":"Freifeld","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121022354567100_CIT0012","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/mmy\/myx130","article-title":"In vitro activity of isavuconazole against fluconazole-resistant isolates of Histoplasma capsulatum","volume":"56","author":"Spec","year":"2018","journal-title":"Med Mycol"},{"key":"2021121022354567100_CIT0013","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/jac\/dkl133","article-title":"Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole","volume":"57","author":"Wheat","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2021121022354567100_CIT0014","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/978-3-319-47266-9_21","article-title":"Antifungal therapy for Histoplasmosis: focus on susceptibility, resistance, and effectiveness in humans and experimental infection","author":"Wheat","year":"2017","journal-title":"Antimicrob Drug Resist"},{"key":"2021121022354567100_CIT0015","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and ID Mycoses Study Group Consensus Group","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021121022354567100_CIT0016","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0002-9343(97)00151-4","article-title":"Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group","volume":"103","author":"Wheat","year":"1997","journal-title":"Am J Med"},{"key":"2021121022354567100_CIT0017","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1086\/588300","article-title":"Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America","volume":"46","author":"Chapman","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021121022354567100_CIT0018","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1093\/cid\/ciw360","article-title":"2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis","volume":"63","author":"Galgiani","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021121022354567100_CIT0019","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1517\/14656566.3.8.1067","article-title":"Management of histoplasmosis","volume":"3","author":"Kauffman","year":"2002","journal-title":"Expert Opin Pharmacother"},{"key":"2021121022354567100_CIT0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mmcr.2019.12.012","article-title":"Achievement of long-term remission of disseminated histoplasmosis in an AIDS patient","volume":"27","author":"Nakamura","year":"2020","journal-title":"Med Mycol Case Rep"},{"key":"2021121022354567100_CIT0021","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/archneur.65.5.666","article-title":"Successful treatment of histoplasmosis brain abscess with voriconazole","volume":"65","author":"Srinivasan","year":"2008","journal-title":"Arch Neurol"},{"key":"2021121022354567100_CIT0022","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1080\/13693780500088416","article-title":"In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi","volume":"43","author":"Gonz\u00e1lez","year":"2005","journal-title":"Med Mycol"},{"key":"2021121022354567100_CIT0023","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1086\/367933","article-title":"Voriconazole: a new triazole antifungal agent","volume":"36","author":"Saravolatz","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2021121022354567100_CIT0024","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1128\/JCM.36.1.198-202.1998","article-title":"In vitro activity of the new triazole voriconazole (UK-109\u2005496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens","volume":"36","author":"Espinel-Ingroff","year":"1998","journal-title":"J Clin Microbiol"},{"key":"2021121022354567100_CIT0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1128\/AAC.46.1.248-250.2002","article-title":"Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS","volume":"46","author":"Wheat","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121022354567100_CIT0026","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1086\/323781","article-title":"Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome","volume":"33","author":"Wheat","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2021121022354567100_CIT0027","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1128\/AAC.41.2.410","article-title":"Hypothesis on the mechanism of resistance to fluconazole in Histoplasma capsulatum","volume":"41","author":"Wheat","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2021121022354567100_CIT0028","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1086\/523576","article-title":"Posaconazole: a broad-spectrum triazole antifungal agent","volume":"45","author":"Nagappan","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2021121022354567100_CIT0029","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1093\/ofid\/ofw172.1346","article-title":"Comparison of posaconazole and itraconazole for treatment of histoplasmosis","volume":"3","author":"Bobbili","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"2021121022354567100_CIT0030","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1086\/313752","article-title":"Practice guidelines for the management of patients with histoplasmosis","volume":"30","author":"Wheat","year":"2000","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1555\/37554530\/ciaa1555.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e3727\/41607903\/ciaa1555.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/73\/11\/e3727\/41607903\/ciaa1555.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T22:36:14Z","timestamp":1639175774000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/73\/11\/e3727\/5929671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,17]]},"references-count":30,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,10,17]]},"published-print":{"date-parts":[[2021,12,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1555","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12,1]]},"published":{"date-parts":[[2020,10,17]]}}}